01:44 , Dec 30, 2016 |  BC Week In Review  |  Clinical News

514G3: Completed Ph I/II enrollment

In December, XBiotech completed enrollment of 36 patients hospitalized with bacteremia due to...
07:00 , Oct 12, 2015 |  BC Week In Review  |  Clinical News

514G3 regulatory update

FDA granted Fast Track designation to 514G3 from XBiotech to treat Staphylococcus aureus infections. The mAb against S. aureus is based on True Human technology and is in Phase I/II testing for the indication. XBiotech...
07:00 , Jun 15, 2015 |  BC Week In Review  |  Clinical News

514G3: Phase I/II started

XBiotech began a double-blind, placebo-controlled, dose-escalation Phase I/II trial to evaluate 3 dose levels of 514G3 in combination with standard IV antibiotic therapy in about 52 patients hospitalized with bacteremia due to S. aureus. XBiotech...